Topics

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.

If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. PAR-17-034: NIDDK Exploratory Clinical Trials for Small Business (R44)

    Release Date: 10-27-2016Open Date: 12-05-2016 Due Dates: Multiple Close Date: 09-05-2019

    Purpose This Funding Opportunity Announcement (FOA) supports applications from Small Business Concerns (SBCs) for exploratory clinical trials that contribute to the justification for a future trial to establish definitive efficacy (such as a Phase 3 clinical trial or a pivotal device trial). This includes Phase 1 and 2 clinical studies of drugs, biologics and biotechnology products, feasibility st ...

    SBIR Department of Health and Human Services
  2. PAR-17-036 : Platform Delivery Technologies for Nucleic Acid Therapeutics (R41/R42)

    Release Date: 10-27-2016Open Date: 12-05-2016 Due Dates: Multiple Close Date: 09-05-2019

    Background There are thousands of rare diseases, and a substantial fraction of these are monogenic disorders, resulting from mutations in a single gene. For such diseases, nucleic acid therapeutics are of potentially broad therapeutic potential. It is important to note, however, that the therapeutic potential of nucleic acids is not limited to rare monogenetic diseases, but also includes more comm ...

    STTR Department of Health and Human Services
  3. PAR-17-035 : Platform Delivery Technologies for Nucleic Acid Therapeutics (R43/R44)

    Release Date: 10-27-2016Open Date: 12-05-2016 Due Dates: Multiple Close Date: 09-05-2019

    Background There are thousands of rare diseases, and a substantial fraction of these are monogenic disorders, resulting from mutations in a single gene. For such diseases, nucleic acid therapeutics are of potentially broad therapeutic potential. It is important to note, however, that the therapeutic potential of nucleic acids is not limited to rare monogenetic diseases, but also includes more comm ...

    SBIR Department of Health and Human Services
  4. PAS-17-064 : Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R43/R44)

    Release Date: 12-02-2016Open Date: 03-05-2017 Due Dates: Multiple Close Date: 09-05-2019

    In the United States (US), it is estimated that more than 5 million people suffer from Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD).  By 2050 this number is forecast to rise to more than 15 million.  Moreover, caring for and treating patients with AD/ADRD is expensive.  Current estimated annual costs for AD/ADRD care and treatment total approximately $20 ...

    SBIR Department of Health and Human Services
  5. PAS-17-065: Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42)

    Release Date: 12-02-2016Open Date: 03-05-2017 Due Dates: Multiple Close Date: 09-05-2019

    In the United States (US), it is estimated that more than 5 million people suffer from Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD).  By 2050 this number is forecast to rise to more than 15 million.  Moreover, caring for and treating patients with AD/ADRD is expensive.  Current estimated annual costs for care and treatment of AD/ADRD total approximately ...

    STTR Department of Health and Human Services
  6. PAR-17-067: Tools for Clinical Care and Management of Alzheimer’s Disease (AD) and its Comorbidities (R43/R44)

    Release Date: 12-02-2016Open Date: 03-05-2017 Due Dates: Multiple Close Date: 09-05-2019

    The principal aim of this SBIR Funding Opportunity Announcement (FOA) is to stimulate research focusing on the development of innovative technologies that would enhance the treatment and clinical management of Alzheimer's disease (AD), Alzheimer's disease-related dementias (ADRD), and their related comorbidities.  Alzheimer's disease (AD) is the leading cause of dementia individuals over the ...

    SBIR Department of Health and Human Services
  7. PAR-17-066: Tools for Clinical Care and Management of Alzheimer’s Disease (AD) and Its Comorbidities (R41/R42)

    Release Date: 12-02-2016Open Date: 03-05-2017 Due Dates: Multiple Close Date: 09-05-2019

    The principal aim of this STTR Funding Opportunity Announcement (FOA) is to stimulate research focusing on the development of innovative technologies that would enhance the treatment and clinical management of Alzheimer's disease (AD), Alzheimer's disease-related dementias (ADRD), and their comorbidities.  The STTR program is designed to expand opportunities for joint-venture opportunities be ...

    STTR Department of Health and Human Services
  8. PA-16-451: Kidney Precision Medicine Project- Technology Development and Validation (R41/R42)

    Release Date: 09-28-2016Open Date: 12-05-2016 Due Dates: Multiple Close Date: 01-05-2020

    Background Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD) impose a significant global health burden. Yet, no effective therapies currently exist for AKI, and only a few are available for CKD. Community feedback indicates that—despite significant effort from industry and academia—development of pharmacologic therapies for AKI and CKD has been hampered by non-predictive animal models ...

    STTR Department of Health and Human Services
  9. PA-16-452: Kidney Precision Medicine Project- Technology Development and Validation (R43/R44)

    Release Date: 09-28-2016Open Date: 12-05-2016 Due Dates: Multiple Close Date: 01-05-2020

    Background Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD) impose a significant global health burden. Yet, no effective therapies currently exist for AKI, and only a few are available for CKD. Community feedback indicates that—despite significant effort from industry and academia—development of pharmacologic therapies for AKI and CKD has been hampered by non-predictive animal models ...

    SBIR Department of Health and Human Services
  10. PAS-17-023 : Development and/or Validation of Devices or Electronic Systems to Monitor or Enhance Mind and Body Interventions (R41/R42)

    Release Date: 10-19-2016Open Date: 12-05-2016 Due Dates: Multiple Close Date: 01-05-2020

    Purpose This Funding Opportunity Announcement (FOA) supports Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) that will develop and/or validate devices or electronic systems that can: 1) monitor biologically- or behaviorally-based processes applicable to mind and body interventions or 2) be used to assist in optimizing the practice or increasing the ...

    STTR Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government